Cipla is currently trading at Rs. 1156.75, up by 10.30 points or 0.90% from its previous closing of Rs. 1146.45 on the BSE.
The scrip opened at Rs. 1146.45 and has touched a high and low of Rs. 1164.50 and Rs. 1146.00 respectively. So far 434237 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,164.50 on 25-Oct-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021.
Last one week high and low of the scrip stood at Rs. 1164.50 and Rs. 1117.65 respectively. The current market cap of the company is Rs. 93359.49 crore.
The promoters holding in the company stood at 33.61 % while Institutions and Non-Institutions held 48.98% and 17.40% respectively.
Cipla’s US-based arm is recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution, which is used to help control the symptoms of chronic obstructive pulmonary disease (COPD). The company is recalling the affected lot due to ‘lack of assurance of sterility: environmental monitoring failure’.
The affected lot has been produced by Cipla at its Madhya Pradesh based plant. Cipla commenced the Class II recall in the US on September 30, 2022. As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: